Literature DB >> 7229107

Serial study of C-reactive protein during infection in leukaemia.

P E Rose, S A Johnsdon, M Meakin, P H Mackie, J Stuart.   

Abstract

Serum C-reactive protein was studied serially by a 1-hour laser nephelometric assay in 25 patients with leukaemia who developed 34 episodes of infection. The serum level rose above, or by, 100mg/l in 29 of the episodes. Serial measurement of this acute-phase reactant was of value in detecting infection in the neutropenic patient and in monitoring the response to antibiotic therapy.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7229107      PMCID： PMC1146475          DOI： 10.1136/jcp.34.3.263

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  5 in total

1.  Five-year analysis of protective isolation.

Authors:  J Lynch; B Jameson; D R Gamble; H E Kay
Journal:  Lancet       Date:  1971-05-22       Impact factor: 79.321

2.  A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients.

Authors:  J W Yates; J F Holland
Journal:  Cancer       Date:  1973-12       Impact factor: 6.860

3.  C-reactive protein for rapid diagnosis of infection in leukaemia.

Authors:  P H Mackie; R A Crockson; J Stuart
Journal:  J Clin Pathol       Date:  1979-12       Impact factor: 3.411

4.  Co-trimoxazole for prevention of infection in acute leukaemia.

Authors:  A Enno; D Catovsky; J Darrell; J M Goldman; J Hows; D A Galton
Journal:  Lancet       Date:  1978-08-19       Impact factor: 79.321

5.  Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia.

Authors:  R A Storring; B Jameson; T J McElwain; E Wiltshaw
Journal:  Lancet       Date:  1977-10-22       Impact factor: 79.321
  5 in total
  23 in total

1.  C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation.

Authors:  C de Bel; E Gerritsen; G de Maaker; A Moolenaar; J Vossen
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

2.  C-reactive protein concentration in suspected bacteraemia.

Authors:  M S Dryden
Journal:  J Clin Pathol       Date:  1986-12       Impact factor: 3.411

3.  Can the rapid semiquantitative estimation of serum C reactive protein be adapted for the management of bacterial infection?

Authors:  N P Richards; T S Elliott; R J Powell; C O'Callaghan; P Franklin
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

Review 4.  Tests for detecting and monitoring the acute phase response.

Authors:  J Stuart; J T Whicher
Journal:  Arch Dis Child       Date:  1988-02       Impact factor: 3.791

5.  Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection.

Authors:  F Voulgari; P Cummins; T I Gardecki; N J Beeching; P C Stone; J Stuart
Journal:  Br Heart J       Date:  1982-10

6.  Value of serum C-reactive protein measurement in the management of bone marrow transplant recipients. Part I: Early transplant period.

Authors:  S A Walker; T R Rogers; P G Riches; S White; J R Hobbs
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

7.  C reactive protein rapid assay techniques for monitoring resolution of infection in immunosuppressed patients.

Authors:  R I Harris; P C Stone; A G Hudson; J Stuart
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

8.  Serial concentrations of C-reactive protein as an indicator of urinary tract infection in patients with spinal injury.

Authors:  A Galloway; H T Green; J J Windsor; K K Menon; B P Gardner; K R Krishnan
Journal:  J Clin Pathol       Date:  1986-08       Impact factor: 3.411

9.  C-reactive protein as an indicator of infection in the immunosuppressed child.

Authors:  M Grønn; S H Slørdahl; S Skrede; S O Lie
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

10.  Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease.

Authors:  C C Zielinski; P Preis; P Aiginger; M M Eibl
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.